IGF1 and lung cancer: Moreover, release of adrenaline and noradrenaline, the physiological ligands for β-AR, upon binding of nicotine to α7nAChRs, activates the β-AR which, in turn, stimulates release of EGF and IGF, thereby promoting growth and proliferation contributing to lung cancer progression [7,48].